Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 diabetes.
New trial finds liraglutide reduces brain shrinkage by nearly 50% in Alzheimer’s patients and slows cognitive decline by up to 18% ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...
The World Health Organization (WHO) has issued its first-ever global guideline recommending that GLP-1 medicines (like those ...
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...
Liraglutide significantly improves hepatic steatosis and metabolic parameters among patients with MASLD — without meaningful reductions in liver stiffness.
The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating obesity as a chronic illness. In a press release, the WHO said ...
9don MSN
Alzheimer's breakthrough as weight loss jab is found to slow progression of memory robbing illness
Liraglutide - sold under the brand name Saxenda - is often offered to people with with a BMI of over 30 as it improves blood ...
The World Health Organization on Monday released new guidance on GLP-1 medications for adults with obesity, recommending ...
A new study from the University of North Carolina has helped doctors and patients better understand which medications are ...
GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in ...
Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid fundamentals, and attractive dividend yield.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback